Corporate
2022.07.28
Lumosa Presenting at 2022 Bio Asia-Taiwan
Corporate
2022.07.13
Lumosa nominated for the "Taiwan Bioprocessing Excellence and Innovation" Award
Corporate
2022.07.11
Lumosa Therapeutics is pleased to introduce our new CBO, Mr. Christopher Aleong
Corporate
2022.06.06
Lumosa's LT1001 approved by Malaysian DCA!
Corporate
2022.05.24
Lumosa Participating the 2022 BIO International Convention
Corporate
2022.03.25
Taiwan FDA Approved the Phase 2 IND for Multiple-dosing of LT3001